IMARC Group’s report titled “Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The global cancer vaccine market share, size, trends, growth, analysis and report. The global cancer vaccines market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2028, exhibiting a growth rate (CAGR) of 11.61% during 2023-2028.
Cancer vaccines are a class of immunotherapies designed to stimulate the immune system of the patient to recognize and combat cancer cells. They include therapeutic vaccines that help treat existing cancer by stimulating the immune system to attack cancer cells, potentially reducing tumor growth and improving patient outcomes. They are often combined with other immunotherapies, such as immune checkpoint inhibitors, to enhance the immune response. They result in fewer side effects compared to traditional cancer treatment methods as they primarily target cancer cells, sparing healthy tissue.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/cancer-vaccines-market/requestsample
Cancer Vaccines Market Trends and Drivers:
Additionally, the growing prevalence of breast, lung, and prostate cancer is driving the demand for efficient treatment and vaccines. Apart from this, continuous improvements in healthcare infrastructure are making vaccines more accessible to a larger population. Furthermore, the governing authorities and non-government organizations (NGOs) are organizing awareness, which is offering a favorable market outlook. These campaigns focus on educating the masses about the importance of early diagnosis and vaccination, significantly increasing the immunization rate. They are also providing funds for cancer research, which is impelling the market growth. Moreover, advancements in biotechnology and vaccine research are enabling the development of more targeted and efficacious vaccines, broadening their application and utility. Investment in research and development (R&D) projects accelerates the vaccine discovery process and fosters innovation, opening doors for next-generation cancer vaccines. Besides this, various pharmaceutical companies are also actively engaging in collaborations and mergers and acquisitions (M&A) to extend their portfolio and market reach. Such strategic alliances often result in the accelerated development of new vaccines, further fueling the market growth. Moreover, the development of novel vaccine types, like deoxyribonucleic acid (DNA) cancer vaccines and therapeutic cancer vaccines, is offering a tailored approach to cancer treatment based on the genetic makeup of an individual, thus making the vaccines more effective. In addition, the rising shift towards personalized medicine is another significant factor driving the market.
Competitive Landscape with Key Player:
- Anixa Biosciences Inc.
- Dendreon Pharmaceuticals LLC
- Dynavax Technologies Corporation
- GSK plc
- Merck & Co. Inc.
- Moderna Inc.
- OSE Immunotherapeutics
- Providence Therapeutics
- Sanofi S.A.
- UbiVac Inc.
- Vaccitech PLC
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Type:
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
Breakup by Technology:
- Dendritic Cells Cancer Vaccines
- Recombinant Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Whole-cell Cancer Vaccines
Breakup by Indication:
- Cervical Cancer
- Prostate Cancer
- Others
Breakup by End User:
- Pediatrics
- Adults
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
Email: [email protected]
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal
About The Author
